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Abstract: Viral recombination is a key mechanism in the evolution and diversity of noroviruses.
In vivo, synchronous single-cell coinfection by multiple viruses, the ultimate prerequisite to viral
recombination, is likely to be a rare event and delayed secondary infections are a more probable
occurrence. Here, we determine the effect of a temporal separation of in vitro infections with the two
homologous murine norovirus strains MNV-1 WU20 and CW1 on the composition of nascent viral
populations. WU20 and CW1 were either synchronously inoculated onto murine macrophage cell
monolayers (coinfection) or asynchronously applied (superinfection with varying titres of CW1 at
half-hour to 24-h delays). Then, 24 h after initial co-or superinfection, quantification of genomic copy
numbers and discriminative screening of plaque picked infectious progeny viruses demonstrated
a time-dependent predominance of primary infecting WU20 in the majority of viral progenies.
Our results indicate that a time interval from one to two hours onwards between two consecutive
norovirus infections allows for the establishment of a barrier that reduces or prevents superinfection.
Keywords: norovirus; murine norovirus; coinfection; superinfection; superinfection exclusion; interference
1. Introduction
Human noroviruses (HuNoVs) are recognised as a leading global cause of spo-
radic and epidemic viral gastroenteritis [1] and account for a global economic burden
of $60 billion, over one million hospitalisations, and 200,000 deaths per annum [2,3]. Cus-
tomarily an acute and self-limiting illness, HuNoV infection can become chronic in the
elderly, malnourished, and/or immunocompromised; such patients may experience pro-
tracted severe, even lethal, NoV infections and superinfections [4–8].
Various HuNoV infection models have yielded valuable insights into the NoV life cycle
in recent years [9–12]. However, many of these experimental systems are technically chal-
lenging and as yet lack the degree of robustness required for detailed decipherment. The
genetically and biologically closely related murine norovirus (MuNoV), which combines
the advantages of available tools for genetic manipulation [13,14], easy in vivo infection
of a genetically tractable native host [15], and efficient in vitro propagation [15–17], thus
remains the main model for NoV in vitro studies.
Human noroviruses and MuNoVs belong to the Norovirus genus within the Caliciviridae
family of small, non-enveloped, positive sense, single-stranded RNA viruses [18,19]. The
linear, polyadenlyated 7.4–7.7 kb long HuNoV genome is organised into three open reading
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frames (ORFs); an additional fourth ORF is described for MuNoVs [20,21]. The 5′ proximal
NoV ORF1 encodes a large polyprotein that is co-and post-translationally cleaved into six
non-structural viral proteins [22]. ORF2 and ORF3 encode the structural virion components,
major and minor capsid proteins, VP1 and VP2, respectively. ORF4, which entirely overlaps
the 5′end of ORF2, encodes virulence factor (VF1) [23].
Viral recombination is a key mechanism in the evolution and diversity of NoVs; in-
creasing evidence indicates that recombination shapes NoV pathogenesis and fitness and
drives the evolution of emerging strains [24]. Numerous field recombination events, pre-
dominantly at a typical ORF1/2 recombination breakpoint [25], have been detected in silico
in the Norovirus genus [26,27]. In contrast, few experimental data are available concerning
NoV recombination under laboratory conditions and the mechanism(s) involved are poorly
characterised [26,28–30].
We recently identified a set of checkpoints, including their respective drivers and
constraints, that must be successfully bypassed for the generation of a viable recombinant
NoV [26,31]. Following this, host coinfection, single cell coinfection, and recombination
must be accomplished to generate a recombinant NoV RNA. An incipient recombinant
viruses must then survive a process of functional selection to be maintained in the viral
population [32–35]. The rise of recombinant viruses resulting from this process is influenced
by different factors. In vivo, host coinfection may be dependent on spatial and temporal
overlap of strain-distributions. Cell coinfection, the ultimate prerequisite to viral recombi-
nation, depends on factors influencing the within-host distribution of viruses to target cells,
thereby limiting or increasing the likelihood of cellular coinfections. True coinfection of
cells is likely to be a rare event (unless mediated by factors directing synchronous uptake of
diverse viruses into both host and cell [36] under natural conditions and delayed secondary
infections are a more probable occurrence.
In the event of an asynchronous infection, the uptake of multiple viruses into a single
cell is dependent on factors that may limit consecutive entry of more than one virus particle
per cell in a process known as superinfection exclusion. Superinfection exclusion is defined
as the ability of an established virus to prevent a secondary infection by the same or
a closely related virus [37]. The primary infecting virus may render cells refractory to
subsequent infection through interference at various stages of the replicative cycle of the
secondary invader in a time-dependent manner. Viral pre-and post-entry blocks have been
described for a number of RNA viruses [38–46]. However, hitherto, NoVs have not been
listed amongst them.
Here, we determine the effect of a temporal separation of in vitro infections with the
two homologous parental MuNoV strains MNV-1 WU20 and CW1 on the composition
of MuNoV populations. A clear advantage of in vitro systems to study viral population
dynamics is that they present a well-defined entity containing only viruses and cells.
Effects of other factors interfering with cell coinfection (such as the host immune response
or microbiome) may thus be discounted.
Our results demonstrate that a time interval from one to two hours onwards between
two consecutive NoV infections allows establishment of a barrier that reduces or prevents
superinfection; this first demonstration of time-dependent viral interference for NoVs has
clear implications for NoV epidemiology, risk assessment, and potentially treatment.
2. Materials and Methods
A graphical overview of all assays is provided in Figure 1.
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becco’s modified Eagle’s medium (DMEMc) (Invitrogen, San Diego, CA, USA, Thermo 
Fisher Scientific, Waltham, MA, USA) containing 10% heat inactivated foetal calf serum 
(FCS) (BioWhittaker), 2% of an association of penicillin (5000 SI units mL−1) and strepto-
mycin (5 mg ml−1) (PS, Invitrogen), and 1% 1 M HEPES buffer (pH 7.6) (Invitrogen) at 37 
°C with 5% CO2. 
Murine NoV isolates MNV-1 CW1 and WU20 (GenBank accession numbers 
DQ285629 and EU004665.1; 87% nucleotide sequence similarity; previously shown to ex-
hibit highly similar replication kinetics [28,47] were plaque purified and propagated in 
RAW 264.7 cells as described by Mathijs et al., 2010 [28]. Virus stocks were produced by 
infection of RAW 264.7 cells at a multiplicity of infection (MOI, expressed as plaque form-
ing units per cell) of 0.05. Two days post-infection, cells and supernatants were harvested 
and clarified by centrifugation for 20 min at 1000× g after three freeze/thaw cycles (−80 °C 
alternating with 37 °C). Supernatants were purified by ultracentrifugation on a 30% su-
crose cushion in a SW28 rotor (Beckman Coulter, Indianapolis, IN, USA) at 23,000 rounds 
per min for 2 h at 4 °C. Pellets were suspended in 500 µL phosphate-buffered saline (PBS), 
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infections with homologous murine norovirus strains MNV-1 WU20 and CW1. MOI = Multiplicity of
infection; ORF = Open Reading Frame; qPCR = quantitative polymerase chain reaction.
2.1. Viruses and Cells
The murine macrophage cell line RAW264.7 (ATC TIB-71) was maintained in Dul-
bec o’s modified Eagle’s medium (DMEMc) (Invitrogen, San Diego, CA, USA, Thermo
Fisher Scientific, Waltham, MA, USA) containing 10% heat inactivated foetal calf serum
(FCS) (BioWhittaker), 2% of an association of penicillin (5000 SI units mL−1) and strepto-
mycin (5 mg ml−1) (PS, Invitrogen), and 1 1 HEPES buffer (pH 7.6) (Invitrogen) at
37 ◦C with 5% CO2.
Murine NoV isolates MNV-1 CW1 and WU20 (GenBank accession numbers DQ285629
and EU004665.1; 87% nucleotide sequence similarity; previously shown to exhibit highly
similar replication kinetics [28,47] were plaque purified and propagated in RAW 264.7 cells
as described by Mathijs et al., 2010 [28]. Virus stocks were produced by infection of RAW
264.7 cells at a multiplicity of infection (MOI, expressed as plaque forming units per cell)
of 0.05. Two days post-infection, cells and supernatants were harvested and clarified by
centrifugation for 20 min at 1000× g after three freeze/thaw cycles (−80 ◦C alternating
with 37 ◦C). Supernatants were purified by ultracentrifugation on a 30% sucrose cushion in
a SW28 rotor (Beckman Coulter, Indianapolis, IN, USA) at 23,000 rounds per min for 2 h at
4 ◦C. Pellets were suspended in 500 µL phosphate-buffered saline (PBS), aliquoted, and
frozen at −80 ◦C. Viral titres were determined via plaque assay for the seventh passage of
WU20 and the eighth of CW1 (WU20 P7 and CW1 P8), as described by Hyde et al., 2009 [48].
WU20 P7 and CW1 P8 single-step and multi-step growth curves, performed prior to
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launching the co-and superinfection experiments described below, exhibited no significant
differences in the replication kinetics of the two virus stocks (Supplementary Figure S1).
2.2. Coinfection and Superinfection of RAW264.7 Cells with Murine Noroviruses WU20 and CW1
Monolayers of RAW 264.7 cells were prepared in 24-well plates at a density of
5 × 104 cells per well. Working on ice, each well was infected with WU20 (MOI = 1;
confirmed via back-titration). After 1 h, the WU20 inoculums (300 µL) were removed and
stored at −80 ◦C. The cells were washed twice with PBS and were infected with CW1
at various MOIs (0.1; 1; 10; confirmed via back-titration) at delays of 0 min (coinfection),
30 min, and 1, 2, 4, 8, 12, and 24 h (superinfections). For coinfections, CW1 and WU20
inoculums in a final volume of 300 µL were simultaneously added to cells. Cells and virus
then remained on ice for 1 h, whereupon the inoculum was removed. For superinfec-
tions, CW1 inoculums were asynchronously dispensed onto cells at the appropriate delays,
whereupon cells and virus remained on ice for 1 h until removal of the inoculums; the cells
were then washed twice with PBS and 300 µL DMEMc were added. Twenty-four hours
post co-or superinfection, both cells and supernatants were frozen and stored at −80 ◦C
until further analysis.
2.3. Quantification of WU20 and CW1 Genomic Copies in Viral Progenies 24 h Post Co-
or Superinfection
RNA extractions were performed with Tri Reagent solution (Ambion, Austin, TX, USA)
on 120 µL of co-and superinfection supernatants. Extracted RNA was reverse-transcribed
into complementary DNA (cDNA) using an iScript cDNA Synthesis kit (Bio-Rad, Hercules,
CA, USA). The extracted and reverse-transcribed cDNA was quantitatively analysed via
real time quantitative PCR (qPCR), employing primers to allow discrimination between
CW1 and WU20 based upon single nucleotide polymorphisms (SNPs) at the 5′ genomic
extremity (amplicon in ORF1, dubbed region 1), as described by Mathijs et al. 2010.
Primers and probes used in the quantification of genomic copies correspond to those listed
in Supplementary Table S1 as published by Mathijs et al., 2010 [28].
Quantifications were performed as previously described by Mauroy et al. (2012) [49];
for generation of the standard curve, region 1 amplicons were amplified for both CW1
and WU20, then cloned into a pGEMt-Easy vector (Promega, Madison, WI, USA) and
sequenced. Both CW1-region 1 and WU20-region 1 plasmids were in vitro transcribed with
the Ribomax kit (Promega) following manufacturer’s instructions. Briefly, SpeI-linearised
and purified plasmids were transcribed with T7 RNA polymerase, treated with DNAse,
and quantified via spectrophotometer. Genomic copy numbers of transcribed RNA were
deduced and serial ten-fold dilutions were prepared with ultrapure RNAse free water
(Invitrogen). Aliquots of the master stock were stored at −80 ◦C and measured before
dilution and use. Final results were normalised using transcripts of the housekeeping gene
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Barber et al. 2005). A 5 µL qPCR
mix (technical duplicates) was set up by adding 1 µL of cDNA to 2.50 µL of iQ supermix,
0.1 µL of both GAPDH-forward and -reverse primers (100 nM final concentration), 0.2 µL of
the GAPDH-probe (200 nM final concentration) and 1.1 µL of nuclease free water. Cycling
conditions included an initial 5-min denaturation at 95 ◦C followed by 38 cycles of 10 s at
95 ◦C and 40 s at 60 ◦C.
2.4. Isolation and Screening of Infectious Progeny Viruses
Cells and supernatants from the co- and superinfection step were frozen and thawed
once and then utilised as inoculums in a plaque assay for purification of infectious progeny
viruses following the method described by Hyde et al. 2009 with slight modifications [48].
Briefly, RAW 264.7 monolayers, cultured in six-well plates (2 × 106 RAW264.7 cells/well)
were inoculated at room temperature with 1 mL of serial dilutions of virus-containing
culture fluids of the co- and superinfection assays. After 1 h, inoculums were removed
and cells were overlaid with 2 mL of medium containing 70% DMEM-Glutamax (4.5 g
glucose l-1 and 15 mM sodium hydrogen carbonate), 2.5% FCS, 2% PS, 1% HEPES and 0.7%
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SeaPlaque agarose (Lonza, Basel, Switzerland) per well. After 48 h of incubation (37 ◦C, 5%
CO2), 36 individual plaques were randomly selected per condition. Infected cells from the
plaque margins were picked with a needle under a microscope and were diluted into fresh
DMEMc before propagation by inoculation onto RAW 264.7 cells grown in 24-well plates.
After 72 h, supernatants were collected and frozen at −80 ◦C until further analysis.
Following RNA extraction and reverse transcription, cDNAs of individual plaque-
purified virus progenies were analysed via two parallel real time PCR runs employing
two pairs of primers to allow discrimination between CW1, WU20 (and recombinant)
signals based upon single nucleotide polymorphisms (SNPs) at both genomic extremities
(ORF1 and ORF3, dubbed regions 1 and 5, respectively) as described by Mathijs et al.
2010 [28]. Five µl reactions were carried out with iQ supermix. Primers and probes for this
TaqMan-based discriminative qPCR correspond to those listed in Supplementary Table S1
as published by Mathijs et al. 2010 [28].
In the case of ambiguous signals originating from mixed virus populations, an additional
quick screen was performed via Sanger sequencing of the ORF1/2 overlap (base pairs 4864
to 5298 in MNV-1 CW1), this to exclude the presence of potential recombinants or PCR
chimeras from interfering with later calculations of WU20 to CW1 infectious virus ratios.
3. Results
3.1. Absolute and Relative Quantification of Genomic Copies Reveals Skewed WU20 and CW1
Distributions and a WU20 Dominance in Most Viral Progenies 24 h Post Co- or Superinfection
To quantitatively assess viral progeny distributions 24 h after initial co-or superin-
fection, MNV-1 WU20 and CW1 genomic copy numbers were inferred from the cycle
threshold (Ct) values of the qPCR reactions and normalised against GAPDH Ct values.
This genomic quantification (5′ region 1 amplicon) revealed WU20 absolute genomic copy
numbers, averaging 3.55 (±0.57) log10 genomic copies over all measured time points, to
be higher than those of CW1 in all but four of the resulting 24 viral progenies. Only short
superinfection delays (t0 h, 0.5 h, 1 h, 2 h) with a WU20 to CW1 starting ratio of one to
ten resulted in CW1 genomic copy numbers significantly higher than or equal to those of
WU20 24 h post co- or superinfection at 3.23 (±0.96), 3.44 (±0.48), 3.74 (±0.09), and 3.93
(±0.06) log10, respectively (Figure 2, top panels).
These absolute genomic copy numbers translate into relative ratios of genomic copies
that reflect a disproportionate WU20 dominance within the majority of viral populations
(Figure 2, bottom panels). A WU20 to CW1 starting MOI ratio of 1 to 0.1 (expected to yield
90% WU20 and 10% CW1 genome copies upon qPCR analysis of the viral population)
yielded mean WU20 genomic copy numbers of 3.40 (±0.43), 3.17 (±0.34), 3.33 (±0.40), and
4.27 (±0.05) log10 (accounting for 95.98%, 92.46%, 91.74%, and 95.73% of the population)
24 h after either coinfection (t0) or superinfections with delays of half an hour (t0.5) to
two hours (t2). From a superinfection delay of four hours (t4) onwards, WU20 mean
genomic copy numbers ranging from 3.28 (±0.56) to 4.24 (±0.01) log10 (99.43 to 99.96% of
the population) are juxtaposed against CW1 values of 1.43 (±0.81) to 0.07 (±0.32) log10.
At an equal WU20 to CW1 starting MOI of 1 (expected yield to 50% WU20 and 50%
CW1 genome copies), 3.17 (±0.33) log10 (77.30%) WU20 to 2.49 (±0.54) log10 (22.69%) CW1
(t0) and 2.98 (±0.78) log10 (62.64%) WU20 to 2.89 (±0.59) log10 (37.36%) CW1 ratios (t0.5),
are succeeded by a marked increase of the WU20 proportion, covering 4.27 (±0.11) (77.63%)
(t1), 4.17 (±0.18) (89.26%) (t2), and 3.37 (±0.04) log10 (86.01%) (t4), and then reaching values
of over 3.16 (±0.47) log10 (95%) from t8 onwards, while CW1 values are consistently at
least one order of magnitude lower and never surpass 2.67 (±0.02) log10 from t4 onwards.
A WU20 to CW1 starting MOI ratio of 1 to 10 (expected to yield 10% WU20 and 90%
CW1 genome copies) resulted in 3.66 (±0.24) log10 to 3.23 (±0.96) log10 and 3.88 (±0.09)
to 3.44 (±0.48) log10 WU20 to CW1 genome copies at t0 and t0.5, respectively (roughly
50–50 ratios), fulfilled expectations with 2.2 (±0.59) log10 WU20 to 3.74 (±0.09) log10 CW1
genome copies (6.16% WU20 to 93.84% CW1) at t1, after which WU20 genome copy
numbers progressively increased to 3.76 (±0.01), 3.68 (±0.29), 4.16 (±0.3), 3.09 (±0.63),
and 3.19 (±0.32) log10 (accounting for 37.85%, 61.66%, 81.67%, 71.20%, and 74.58% of
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the population) at t2, t4, t8, t12, and t24, respectively. CW1 genome copy numbers
correspondingly decreased.
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and 10 (right panels). Black bars represent WU20, grey bars represent CW1. Differences in yield between mean WU20 and 
CW1 genome copies were analysed using GraphPad Prism 7 (Graph-Pad Software) and p values were determined using 
two-sided unpaired-sample t tests, where *** p ≤ 0.001, ** p ≤ 0.01, and * p ≤ 0.05. 
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of mean genomic c p es (below) of co- or superinfecti g murine noroviruses MNV-1 WU20 and CW1 in viral p ogenies
24 h post co- or superinfection. Ge omic copy numbers and their relative proportions resulting from one c -infection (t0)
and seven asynchronous infections (primary infection: WU20; superinfection at half-hour to 24-h delays (t0.5 to t24): CW1)
are shown. Varying multiplicities of infection (MOI) were analysed; the MOI of primary infecting WU20 remained stable
at 1 throughout all assays while the MOI of superinfecting CW1 varied between 0.1 (left panels), 1 (middle panels), and
10 (right panels). Black bars represent WU20, grey bars represent CW1. Differences in yield between mean WU20 and
CW1 genome copies were analysed using GraphPad Prism 7 (Graph-Pad Software) and p values were determined using
two-sided unpaired-sample t tests, where *** p ≤ 0.001, ** p ≤ 0.01, and * p ≤ 0.05.
3.2. Molecular Screening on Picked Lysis Plaques Demonstrates a WU20 Predominance in the
Majority of Infectious Viral Progenies
To isolate and screen infectious progeny viruses present within the various viral
populations 24 h after initial co-or superinfection, 36 viral plaques per condition were
picked from a plaque assay, further propagated in RAW246.7 cells, and then analysed in
parallel duplex qPCR runs to discriminate between MNV-1 CW1 and WU20 (as well as
possible recombinant viruses) based on 5′ and 3′ SNPs. In three cases, additional ORF1/2
screening confirmed sequence kinship to either WU20 or CW1.
Overall, the previously observed WU20 dominance, particularly following longer
CW1 superinfection delays, is mirrored in the proportions of plaque picked infectious
viruses (Figure 3). Thus, a WU20 to CW1 starting MOI ratio of 1 to 0.1 (expected to yield
infectious progeny virus proportions of 90% WU20 to 10% CW1) yielded 94%, 68%, 83%,
84%, 100%, 88%, 100%, and 100% WU20 24 h after coinfection (t0) or superinfection delays
of half an hour (t0.5) to 24 h (t24), respectively. Pure CW1 fractions are seen to account
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for 3%, 16%, and 6% of infectious viral populations at t0, t0.5, and t1. However, with the
exception of the eight-hour superinfection delay (3% CW1 at t8), CW1 is not represented in
infectious virus progenies from t2 onwards. Mixed WU20 and CW1 progenies make up the
remaining fractions of the various populations.
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A WU20 to CW1 starting MOI ratio of 1 to 10 (expected to yield infectious progeny 
virus proportions of 10% WU20 to 90% CW1) resulted in WU20 proportions of 3% follow-
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Figure 3. Relative proportions of viable co- or superinfecting murine noroviruses MNV-1 WU20 and CW1 after plaque
purification and amplification. Black bars show the proportion of WU20, grey bars show the proportion of CW1, and
striped bars indicate mixed signals of both WU20 and CW1 in viral progenies amplified from 36 plaques per condition. One
coinfection (t0) and seven asynchronous infections (primary infection: WU20; superinfection at half-hour to 24-h delays (t0.5
to t24): CW1) and varying multiplicities of infection (MOI) were analysed; the MOI of primary infecting WU20 remained
stable at 1 throughout all assays while the MOI of superinfecting CW1 varied between 0.1 (left panel), 1 (middle panel), and
10 (right panel)).
At an equal WU20 to CW1 starting ratio (expected to yield balanced infectious WU20
and CW1 proportions), initial 76% WU20 to 9% CW1 (plus 15% mixed) and 9% WU20
to 50% CW1 (plus 41% mixed) ratios at t0 and t0.5 are succeeded by a marked increase
of the WU20 proportion. WU20 thus accounts for 67%, 71%, and 52% of infectious viral
progenies at t1, t2, and t4, and consistently reaches values of over 94% from an eight-hour
superinfection delay (t8) onwards. CW1 and mixed progeny proportions correspondingly
decrease following the one-hour superinfection delay (t1).
A WU20 to CW1 starting MOI ratio of 1 to 10 (expected to yield infectious progeny
virus proportions of 10% WU20 to 90% CW1) resulted in WU20 proportions of 3% following
coinfection (t0) and 6%, 0%, and 3% following early superinfection delays (t0.5 to t2). From
t4 onwards, WU20 quantities are seen to progressively increase, accounting for 21% (t4),
46% (t8), and 100% (t12 and t24) of infectious virus progenies.
4. Discussion
Viral recombination has been identified as a key mechanism shaping the evolution
and diversity of NoVs [24,26,27]. In contrast to an abundance of field data, few experi-
mental data are available concerning NoV recombination and the mechanism(s) involved
remain poorly characterised [26,28–30,50]. An incremental step in the generation of any
recombinant viral RNA and consequently any viable recombinant virus is the successful si-
multaneous infection of a single cell by (a minimum of) two viruses [32–35]. Under natural
conditions, various environmental, host, and virus factors may influence the probability of
synchronous coinfections and may determine the delay or even the absolute achievability
of asynchronous cellular superinfections. Superinfection exclusion, whereby a primary
infecting virus may render cells refractory to subsequent infection through interference
at various stages of the replicative cycle of the secondary invader [37], is a typically virus-
mediated process. Viral pre-and post-entry blocks have been described for a number of
RNA viruses [38–45]. Hitherto, NoVs have not been listed amongst them.
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Here, we determined the effect of a temporal separation of in vitro infections with the
two homologous MuNoV strains MNV-1 WU20 and CW1 on the composition of nascent
MuNoV populations. In utilising an in vitro system, we excluded both environmental
and host influences and were thus able to examine only those effects mediated by the
viruses themselves.
Subsequent to initial WU20 and CW1 cell coinfections or superinfections with half-
hour- to 24 h-delays and varying input MOIs (1:0.1; 1:1; 1:10), followed by a 24-h propaga-
tion step, individual viral progeny distributions were analysed via qPCR. This quantitative
analysis revealed a disproportionate dominance of primary infecting WU20 genomic copies
in the majority of resulting viral progenies. While the WU20 dominance appeared to be
near-independent of the input MOI ratios of the two viruses (and indeed skewed expected
genomic copy ratios throughout), it was markedly time-dependent; increasing CW1 super-
infection delays from one to two hours onwards were associated directly with increasing
WU20 genome copy fractions. While primary infecting WU20 is expected to have under-
gone a round of replication before addition of CW1 at superinfection delays of more than
eight hours (thus inherently tipping the balance of virus ratios in favour of WU20), input
and expected ratios deviate significantly even at earlier time points where this effect cannot
serve to explain the observed WU20 dominance.
Interestingly, the way in which higher-than-expected WU20 genomic copy numbers
skewed expected genomic copy ratios even after coinfections or short superinfection delays
may hint at the mechanism of the pronounced dominance following longer delays. Where
input MOIs of 1:0.1, 1:1, and 1:10 were expected to yield WU20 to CW1 genomic copy ratios
of 90% to 10%, 50% to 50%, and 10% to 90% following coinfection, these expectations were
frustrated in the face of 3.40 (±0.43) to 1.79 (±0.75), 3.17 (±0.33) to 2.49 (±0.54), and 3.66
(±0.24) to 3.23 (±0.96) log10 WU20 to CW1 genomic copy proportions. Vacillating levels of
infectious virus and genomic copies have previously been associated with the presence
of defective interfering (DI) RNAs or DI particles within NoV populations [51]. DI RNAs
or particles, deleterious virus-like by-products of error-prone RNA virus replication, are
known interfere with standard virus particles by competing for resources [52,53]. DI RNAs
may also play a role in mediating superinfection exclusion by induction of RNA silencing
and the homology-dependent degradation of incoming RNA molecules [54]. In this context,
it is conceivable that WU20 DI RNAs within the population (necessarily included in the
quantitative analysis of genome copies since the qPCR assay does not distinguish between
DI RNAs or DI particles and whole (infectious) viral genomes) were recognised by the
cellular RNA silencing machinery and served to guide degradation of incoming CW1 RNA
sequences, this particularly following longer superinfection delays.
Relative proportions of infectious viruses isolated from viral progenies following
coinfection (t0) or short superinfection delays of up to two hours (t0.5 to t2), support
a possible role of WU20 DI RNAs. Thus, e.g., coinfection with a one to ten WU20 to
CW1 MOI ratio resulted in skewed genomic copy ratios of 45.57% WU20 to 54.43% CW1,
but translated into infectious virus ratios of 3% WU20 and 91% CW1 (plus 6% mixed).
Following asynchronous infection with longer delays (t4 to t24), a time-dependent WU20
dominance and corresponding CW1 decrease is evident within infectious virus progenies.
Mixed populations registered subsequent to two-hour superinfection delays may indicate
that that the barrier is established progressively and is, initially, not strong enough to
completely repel superinfecting CW1, especially in the face of high input titres.
Taken together, these results demonstrate that a time interval from one to two hours
onwards between two consecutive in vitro MuNoV infections allows establishment of a
barrier that progressively reduces or prevents superinfection. While viral interference, or
superinfection exclusion, has hitherto not been described for NoVs, it is well documented
for other positive sense, single-stranded RNA viruses, such as hepatitis C-, bovine viral
diarrhoea-, and West Nile virus and may be established within 30 min to several hours of
primary infection [43,44,55–57].
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In future investigations it will be interesting to leverage population-level deep se-
quencing to analyse how the viral interference effects pinpointed here may influence
the generation of NoV RNA recombinants (and thus ultimately influence the chances
of recombinant virus generation under the application of selective pressures). Further
work should also focus on the mechanism of NoV interference (pre-or post-entry mode
of action analysis) and will investigate whether the observed block can be overcome by
superinfecting viruses.
Understanding the influence that viral interference may have on NoV population
dynamics has clear implications for NoV epidemiology and risk assessment. The phe-
nomenon is thought to decrease the evolution of drug resistance and immune escape by
limiting population variability and virus recombination [55]. Identifying where it plays a
role and also where and how it may be overcome in the field by superinfecting variants are
also important in the context of treating NoV infections.
Supplementary Materials: The following data are available online at https://www.mdpi.com/
article/10.3390/v13050823/s1, Figure S1: Growth curves for MNV-1 WU20 and CW1 at low and high
multiplicities of infection (MOI).
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